David Wolk, MD: Utilizing MRI in Alzheimer Disease
July 29th 2019The co-director of the University of Pennsylvania Memory Center will share additional insights on Alzheimer disease at the upcoming International Congress on the Future of Neurology, taking place September 27-28, 2019 in New York City.
Neuromodulation Shows Early Success in Epilepsy Treatment
July 29th 2019The University of Alabama at Birmingham neuromodulation epilepsy clinic has treated 43 patients with drug-resistant epilepsy, reducing seizures by >60% for a number of patients with both vagus nerve stimulation and responsive neurostimulation techniques.
Jeffrey L. Cummings, MD, ScD: Addressing Agitation, Psychosis in Alzheimer Disease
July 28th 2019The director emeritus of the Cleveland Clinic Lou Ruvo Center for Brain Health and vice chair of the department of brain health at the University of Nevada Las Vegas spoke about therapies under investigation for the treatment of agitation and psychosis in Alzheimer disease.
Introducing Innovative Technologies Into Stroke Standard of Care
July 27th 2019The co-director of the Gates Stroke Center and Cerebrovascular Surgery at Kaleida Health and director of endovascular stroke treatment and research medical director of neuroendovascular services at Gates Vascular Institute spoke about unmet needs in stroke and the value of introducing innovative technologies into the space.
Ponesimod Posts Positive Top-Line Data in Phase 3 MS Trial
July 26th 2019Though no details have been reported, Janssen Pharmaceuticals announced that its S1P modulator ponesimod has met its primary and key secondary end points in the OPTIMUM study, in which it was compared to teriflunomide in patients with relapsing MS.
Eptinezumab Effective in Chronic Migraine Prevention in Phase 2b Trial
July 26th 2019The investigators noted that these data provide robust and promising evidence that eptinezumab is associated with a rapid preventive effect in chronic migraine that is sustained for 3 months after a single infusion.
James W. Wheless, MD: Making Treatment Decisions in Epilepsy
July 26th 2019The professor and chief of pediatric neurology at Le Bonheur Children’s Hospital and the University of Tennessee Health Science Center discussed the decision-making process for choosing interventions for patients with epilepsy, and how to keep patients adherent.
PMZ-1620 Enters Phase 3 Trial As a Potential Treatment For Cerebral Ischemic Stroke
July 25th 2019The investigational therapy has the potential to be a first-in-class neuronal progenitor cell therapeutic with anti-apoptotic activity that improves cerebral blood flow and neurological outcome in stroke.
Christopher Gottschalk, MD: Long-Term Safety in Preventive Migraine Therapies
July 25th 2019The director of headache medicine and chief of general neurology at Yale Medicine discussed the long-term success the new preventive migraine therapies have shown thus far, and how the lack of safety concerns will improve how they’re utilized.
MS Relapse Risk Not Increased Post Surgery, Anesthesia
July 25th 2019Despite previous case series suggesting that undergoing surgery may increase the risk of multiple sclerosis relapse, retrospective analysis of more than 600 surgeries undergone by patients with progressive and relapsing MS now proposes that the risk of relapse is not high in the postoperative period.
David Llewellyn, PhD: The Impact of Lifestyle Factors on Genetic Risk in Dementia
July 25th 2019The associate professor of neuroepidemiology and digital health spoke about the importance of findings from an observational study which showed that adherence to a healthy lifestyle can offset the genetic risk for dementia.
Dawn Buse, PhD: Patient Referrals From Primary Care for Migraine
July 24th 2019The clinical professor of neurology at Albert Einstein College of Medicine discussed the referral process for patients with migraine and which patients may be too complex for the limited time primary care physicians have.
Sexually Active Patients With Parkinson Report Lower Motor, Nonmotor Disability
July 24th 2019The PRIAMO study data showed that men with Parkinson disease who had been sexually active in the past 12 months were more likely to have lower motor disability, better quality of life, and lower depression scores. No similar associations were observed for women.
Experts to Discuss Central Issues in Stroke Care at Future of Neurology Congress
July 23rd 2019The International Congress on the Future of Neurology will take place this Fall in New York City, convening experts in neurology to discuss the latest data and best practices to better inform clinical decision-making.
FDA Cites Active Ingredient Issue With Riluzole For Treatment of Amyotrophic Lateral Sclerosis
July 22nd 2019The complete response letter cited issues with an active pharmaceutical ingredient used in the Biohaven 2017 bioequivalence study that was manufactured between 2014 and 2016 in an Apotex facility.
Galcanezumab Reduces Episodic Cluster Headache Attacks, But Fails in Chronic Disease
July 22nd 2019The monoclonal antibody against CGRP reduced the frequency of episodic cluster headache attacks significantly more than placebo, though the Eli Lilly therapy failed to separate from placebo in the disease’s chronic presentation.
James W. Wheless, MD: The Consequences of Uncontrolled Epilepsy
July 22nd 2019The professor and chief of pediatric neurology at Le Bonheur Children’s Hospital and the University of Tennessee Health Science Center spoke about the concerns of uncontrolled epilepsy and how to determine if a patient requires more than one treatment for their epilepsy.
Ubrogepant's Potential in the Migraine Treatment Landscape
July 21st 2019The director of the Headache Center of Southern California shared insight into the success of ubrogepant in patients who failed on triptans, and how the future of migraine treatment may need to focus on combination approaches.